Russia is investing over 2.04 trillion rubles, or $26-28 billion (depending on the exchange rate), in a national health initiative to slow aging. Russian officials say their “New Health Preservation Technologies” project could produce the world’s first anti-aging gene therapy treatment between 2028 and 2030. The government views the initiative as part of a national mission to “preserve the health” of Russians and save 175,000 lives by 2030.
Over the past few years, Russian anti-aging research funded by the Russian Science Foundation has steadily increased. The state-run nonprofit, set up in 2013 to support scientific research, has reportedly grown six times since 2021 compared to the previous five-year period.
Between 2021 and 2025, the RSF supported over 40 aging-focused medical projects. These projects include regenerative medicine, brain aging, immune-system decline, neurotechnology, biological age monitoring, organ bioprinting, and an “anti-aging vaccine,” which has garnered international attention since Russian officials recently announced a breakthrough.
Big Ambitions, Bigger Questions
Not everyone is convinced Russia can deliver on its sweeping promises. Due to economic pressures and other challenges facing Russian science and medicine, independent Russian experts have called some Kremlin goals too ambitious.
Further, economists note that research spending as a share of GDP has steadily declined, while critics question whether Russia’s state-dominated private sector can contribute enough. Scientists also cite worsening funding, sanctions, and international isolation since the Ukraine war as major barriers to scientific and economic growth.
After the 2022 invasion of Ukraine, the U.S. and G7 curtailed research ties with Russian state-linked institutions. In response, reports show that Russia has shifted toward scientific partnerships with China and other Eurasian countries, such as India. Notably, Russia has established new technology agreements with Beijing in 2026, such as a recently reported cancer research joint venture. However, reduced access to Western funding and collaboration platforms has weakened Russia’s global biotech research competitiveness.
Even Kremlin forecasters admit the war economy has stalled. On May 12, the ministry published its updated macroeconomic projection, the first to admit that Russia will stagnate for at least two more years with no rebound.
There are doubts within Russia’s pharmaceutical industry that lie in the premise of value for anti-aging research in Russia. A source said, “Sarcopenia and asthenia are very important medical problems in countries where people live to old age, but in Russia, unfortunately, many people don’t even make it to pension age.
Some researchers doubt Russia has the infrastructure, funding, or international scientific collaboration to compete with US and European biotech leaders. Many doubt government-driven “moonshot” programs can succeed in a field that relies on open international collaboration, cutting-edge infrastructure, and long-term private investment.
Putin’s Personal Fascination With Immortality
The initiative also reflects a longstanding fascination with longevity inside Russia’s political elite—especially Putin himself. The 73-year-old Russian president has cultivated a carefully managed image of vitality, emphasizing fitness, swimming, judo, ice hockey, strict dieting, and outdoor exercise. Reports over the years have additionally linked him to unconventional wellness practices, including controversial “antler baths” marketed as rejuvenation treatments.
However, a leaked video showed Putin coughing uncharacteristically during an International Women’s Day address, a rare blemish on his normally flawless health. In an outtake from a Kremlin-leaked address, Putin splutters for 30 seconds and coughs repeatedly.
Now in his seventies, Putin has repeatedly spoken publicly about extending human lifespan through biotechnology and advanced medicine. During a widely discussed conversation with Chinese leader Xi Jinping, Putin remarked that advances in medicine could eventually allow humans to “feel younger and younger” and perhaps even “achieve immortality.”
But Putin’s alleged ambitions were said to have suffered a setback last year with the death of his long-time anti-aging adviser, Professor Vladimir Khavinson, aged 77. Khavinson, who led the St Petersburg Institute of Bioregulation and Gerontology, said he was working on ways to extend human life to 110 or 120 and called Putin “perfect” compared to Leonid Brezhnev, Yuri Andropov, and Boris Yeltsin.
The Next Space Race?
Declining birth rates, an aging population, emigration, and low male life expectancy—a recent Statista report shows most Russian men live to 67, nearly a decade less than Americans—exacerbate Russia’s demographic crisis. These pressures are reducing the working-age population and straining healthcare and the economy.
With that in mind, Russia’s longevity initiative can be seen as part of a new space race in which nations compete for human lifespan and health rather than rockets for interstellar glory. Along these lines, some critics argue that this initiative risks becoming more political theater than scientific revolution, echoing the space race of the Cold War. Russia’s war in Ukraine, which killed hundreds of thousands of people, coincides with the longevity push. Critics argue that contradiction has made the anti-aging campaign politically charged from the start.
Even small breakthroughs could have huge economic and geopolitical effects. Longer healthy lives could change labor markets, healthcare, retirement, and productivity. That promise is why governments and investors are spending astronomical amounts to slow aging. Whether Russia produces a scientific breakthrough or another biotech dream is unknown. But one thing is clear: Russia has entered the human lifespan arena and intends to put up a fight.
Comments